This educational guide is based on the linked primary sources. It is not a Court publication, is not affiliated with the Court, and is not legal advice.
In brief
Overview
Background and question before the Court
According to Merck KGaA, there is no dispute among the parties, nor among the 19 amicus briefs presented before the Court.
According to United States, the central issue before the Court is the proper construction of the statute.
According to United States, the Court is considering whether the lower courts committed legal errors in interpreting the statute.
Justice Kennedy asked whether the basic research falls within the common law research exemption.
According to Justice O'Connor, justice O'Connor questioned whether the Federal Circuit focused too much on generic drug applications.
What each side argues
Merck KGaA (Petitioner)
According to Merck KGaA, merck KGaA stated that there is no dispute among the parties and the 19 amicus briefs.
According to Petitioner, merck KGaA indicated it would address Justice Scalia's question with an overarching point.
Integra Lifesciences I Ltd. (Respondent)
Source-limited. The record does not yet support a complete account.
What happened at oral argument
According to Chief Justice Rehnquist, chief Justice Rehnquist announced the start of argument.
Justice O'Connor asked for clarification at the start of the case.
According to Justice Scalia, justice Scalia remarked that the issue might determine whether the research was relatively directly related.
Justice O'Connor asked whether the jury instruction correctly states the law.
The Federal Circuit resolved the questions as a matter of law, de novo, without regard to the jury instruction.
Justice Kennedy asked whether the basic research falls within the common law research exemption.
According to Justice O'Connor, justice O'Connor questioned whether the Federal Circuit may have focused too much on generic drug applications.
Justice O'Connor asked for a repetition of a point.
Justice Ginsburg asked where the text being referenced could be found.
Justice Souter asked what was being read from.
According to Justice Stevens, justice Stevens noted that a paragraph referred to effectiveness.
According to Justice Scalia, justice Scalia expressed confusion about the conclusion.
The United States amicus argued that the question before the Court is the proper construction of the statute and that the lower courts committed three legal errors.
The Court previously held in Eli Lilly v. Medtronic that the statute is not limited to generic drugs.
Violating federal law could lead to severe civil and criminal consequences.
- [1] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 3
- [2] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 3
- [3] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 19
- [4] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 20
- [5] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 20
- [6] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 26
- [7] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 35
- [8] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 36
- [9] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 36
- [10] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 37
- [11] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 38
- [12] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 42
- [13] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 17
- [14] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 22
- [15] d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdf, p. 24
What the Court decided
Why it matters
Terms to know
No glossary terms are available for this guide.
Primary sources
Read the source materials on the official site or open the immutable repository copy used for this guide.
- d1d68b383222b522ed49-r1-08cc65ab8c664abd.pdforal argument transcript
Guide generated September 20, 2026. Automated validation accepted this version.